Medicinal Plant Biochemistry Research to Prevent Cancer in Indonesia

Full text

Text extracted from the article PDF for reading and search. Tables, figures and equations are in the PDF, which remains the authoritative version.

1. Introduction

Cancer prevention is a public health priority in Indonesia. While prevention strategies include reducing exposure to carcinogens, improving vaccination and screening programs, and strengthening lifestyle interventions, there is also sustained interest in safe, culturally accepted preventive agents that can complement public health measures. Medicinal plants are widely used and readily accessible, but their contribution to cancer prevention depends on rigorous biochemical evidence, safety assurance, and responsible translation.

Biochemistry provides the bridge from traditional use to mechanistic evidence. Plant-derived polyphenols, terpenoids, alkaloids, polysaccharides, and volatile compounds can modulate pathways relevant to carcinogenesis and early lesion progression: antioxidant responses (e.g., Nrf2), inflammation signaling (e.g., NF‑κB), detoxification balance, cell cycle control and apoptosis, angiogenesis, and immune surveillance. These pathways are multi-factorial and interconnected, implying that prevention research should prioritize mechanism‑aligned assay panels rather than single screening tests.

However, the scientific literature also reveals common pitfalls. Many studies report “anti-cancer” potential from crude extracts based on cytotoxicity or antioxidant assays without establishing prevention relevance, human safety, or reproducibility. Extract composition varies by chemotype, season, and processing, and metabolite identification remains a bottleneck without standards and spectral libraries. In addition, research on Indonesian biodiversity must comply with access-and-benefit sharing (ABS) governance and ethical engagement with local knowledge systems, consistent with the Nagoya Protocol framework (CBD, 2011). This article synthesizes literature up to 2024 to map the challenges and opportunities of Indonesian medicinal plant biochemistry research for cancer prevention and to propose an institutional roadmap for higher education. We address three questions: (1) Which biochemical targets and assay strategies are most relevant to prevention? (2) What challenges constrain credibility and translation in Indonesia? (3) What institutional actions can accelerate rigorous, ethical, and scalable research outputs?

2. Literature Review

2.1. Cancer prevention biochemistry: targets and

evidence logic Cancer arises through multistep processes involving genetic and epigenetic alterations, microenvironmental changes, and dysregulated signaling. Prevention research therefore emphasizes upstream drivers and early lesion control: oxidative stress and DNA damage, chronic inflammation, detoxification balance, cell cycle regulation and apoptosis, angiogenesis and invasion pathways, immune surveillance, and microbiome–metabolite interactions. A prevention‑oriented medicinal plant program should map plant metabolites to these targets, prioritize realistic dosing and exposure routes, and use biomarkers that can translate into human studies.

2.2. Natural products and multi‑target prevention

potential Natural products remain a major source of therapeutic discovery and offer multi-target mechanisms that are relevant to prevention. Large-scale reviews show that natural products contribute substantially to new drugs and provide diverse scaffolds and bioactivities (Newman & Cragg, 2020; Atanasov et al., 2021) [1]. In prevention contexts, plant polyphenols and triterpenoids may modulate oxidative stress and inflammation, while alkaloids and terpenoids may affect cell cycle and apoptosis pathways. However, multi-target potential is not a substitute for evidence: mechanistic claims must be supported by target-aligned assays, dose–response analysis, and safety evaluation.

2.3. Metabolomics, dereplication, and reproducibility in

medicinal plant biochemistry Metabolomics supports comprehensive profiling of plant extracts and can map chemotype variability and identify candidate marker compounds. Foundational framing described metabolomics as a bridge between genotype and phenotype (Fiehn, 2002) [4]. Minimum reporting standards were proposed to improve transparency and comparability (Sumner et al., 2007) [11]. In natural products research, dereplication is essential to avoid rediscovery and to strengthen identification. Wolfender et al. (2019) [16] describe strategies combining LC–MS/MS, NMR, and computational tools, while MS/MS-based molecular networking provides efficient dereplication and comparative analysis (Qin et al., 2022) [9].

2.4. Governance and quality control: ABS and herbal

material standards Research using Indonesian genetic resources must be ethically and legally grounded. The Nagoya Protocol provides an international framework for access to genetic resources and fair benefit-sharing, requiring prior informed consent and mutually agreed terms (CBD, 2011). Governance analyses highlight practical complexities in implementation and collaborations (Oberthür & Rosendal, 2014) [8]. In parallel, herbal research must address quality and safety: WHO guidance emphasizes contaminants, residues, and quality control methods for herbal materials (WHO, 2011). Indonesian regulatory frameworks further differentiate traditional medicine categories and define safety and quality requirements (BPOM, 2019) [2].

3. Method

This article uses a framework synthesis approach. We integrated peer-reviewed literature and authoritative standards and governance sources published up to 2024 to construct an evidence-informed synthesis of medicinal plant biochemistry research relevant to cancer prevention in Indonesia.

We organized sources into five clusters: (1) prevention-relevant cancer biochemistry targets and biomarkers; (2) natural products and multi-target bioactivity; (3) metabolomics and dereplication workflows for medicinal plants; (4) governance and ethics under ABS frameworks; and (5) quality control and standardization guidance for herbal materials and traditional medicines. Results are reported as design-oriented guidance. Figure 1 maps prevention pathways and plant intervention points. Figure 2 presents an evidence‑to‑translation ladder for prevention claims. Tables summarize (1) biochemical targets and assays, (2) challenges and mitigations for Indonesian contexts, and (3) an institutional roadmap and metrics for universities.

4. Results and Discussion

Fig 1: Cancer prevention pathways and medicinal plant biochemistry intervention points Fig 2: Evidence-to-translation ladder for Indonesian medicinal plant biochemistry in cancer prevention Results are presented as a structured synthesis of targets, evidence standards, and institutional strategies. Figure 1 highlights shared prevention-relevant pathways and shows how medicinal plant biochemistry can intervene through multi-target mechanisms. Figure 2 describes an evidence-to-translation ladder designed for prevention claims, emphasizing standardization and human biomarker endpoints.

4.1. Mechanism-aligned targets for prevention and early

Prevention research differs from treatment research: the objective is to reduce risk, delay onset, or slow early progression rather than to cure established malignancy. Therefore, mechanism-aligned targets should prioritize upstream drivers (oxidative stress, inflammation, detoxification balance) and early lesion biology (apoptosis and cell cycle checkpoints, angiogenesis signaling, immune surveillance). A credible study should align its assays to a target panel, report dose–response relationships, and include negative controls and cytotoxicity checks to avoid confounding general toxicity with prevention-relevant modulation.

4.2. Moving beyond the “antioxidant-only” trap. Many herbal studies use DPPH/FRAP assays as primary outcomes. Such assays can support chemical characterization, but they do not establish cancer prevention efficacy in vivo or in humans. Robust research should incorporate cell-based and pathway-based assays (e.g., Nrf2 activation, NF‑κB inhibition, DNA damage markers) and should connect observed effects to specific metabolites. Integrating metabolomics and dereplication early clarifies chemical identity and supports reproducibility (Fiehn, 2002; Sumner et al., 2007; Wolfender et al., 2019; Qin et al., 2022) [4, 11, 16, 9].

4.3. Standardization and safety as prerequisites for

Prevention interventions are typically long-term, making safety and quality non-negotiable. Research should therefore incorporate QA/QC systems: marker panels or fingerprints, contaminant screening, stability tests, and batch-to-batch control. WHO guidance provides a framework for quality control of herbal materials (WHO, 2011), while BPOM regulations define national requirements and categories for traditional medicines (BPOM, 2019) [2]. In practice, the ability to generate standardized extracts often distinguishes publishable mechanistic research from translatable programs.

4.4. Governance and ethics as strategic capabilities. ABS compliance and ethical engagement with local knowledge are sometimes seen as administrative burdens. This synthesis suggests reframing them as strategic capabilities: universities that build ABS workflows, PIC/MAT templates, and benefit-sharing plans can form long-term partnerships and sustain access to biodiversity in a legitimate manner (CBD, 2011; Oberthür & Rosendal, 2014) [8]. Ethical best practice also emphasizes respectful engagement and transparency in ethnopharmacology (Heinrich et al., 2020) [6].

4.5. Institutional roadmap for Indonesian universities. A robust university program should combine: (1) taxonomy and voucher practices, (2) shared analytical infrastructure (LC–MS/MS, NMR, bioinformatics), (3) mechanistic assay platforms aligned to prevention targets, (4) QA/QC and contamination screening capacity, and (5) clinical/public health partnerships for biomarker studies. Stage-gates aligned to the evidence ladder (Figure 2) can prioritize projects and prevent overclaims. Investment in local spectral libraries and open repositories can reduce annotation bottlenecks for Indonesian flora, while cultivation partnerships can support sustainability and consistent chemistry for standardization.

Table 1: Prevention-relevant biochemical targets for cancer and recommended assays for medicinal plant biochemistry research. Target domain Representative targets/biomarkers Recommended assays/models Notes for prevention claims Oxidative stress & DNA damage ROS, 8‑OHdG, DNA repair markers Cell-based ROS; comet assay; oxidative DNA markers Interpret with dose realism; control for cytotoxicity and solvent effects.

Inflammation NF‑κB, COX‑2, cytokine surrogates Reporter assays; cytokine panels; inflammation challenge models Prioritize chronic low-dose contexts relevant to prevention.

Detoxification balance Phase I/II enzymes; Nrf2 pathway Nrf2 reporter; GST/UGT activity; transcript markers Link to carcinogen metabolism models when feasible.

Cell cycle & apoptosis p53, caspases, cyclins Apoptosis assays; cell cycle profiling; caspase activation Use early lesion/preneoplastic models when available; avoid overgeneralization.

Angiogenesis & invasion VEGF, MMPs, EMT markers Endothelial tube formation; MMP assays; migration assays Relevant to early progression; interpret cautiously for prevention.

Immune surveillance T cell activation markers; macrophage polarization Co-culture models; cytokine profiling; immune signaling assays Prevention includes immune modulation; requires careful controls.

Table 2: Challenges and mitigation strategies for cancer-prevention medicinal plant biochemistry research in Indonesia. Challenge Why it matters Mitigation strategy Evidence anchor (≤2024) ABS governance & permits Legitimacy, delays, partnership risk ABS workflow; PIC/MAT templates; legal support CBD (2011); Oberthür & Rosendal (2014) [8] Taxonomy/voucher gaps Misidentification undermines reproducibility Herbarium vouchers; barcoding; expert validation Good practice in plant sciences Chemotype variability Batch inconsistency; weak standardization Sampling design + metadata; metabolomics mapping Fiehn (2002) [4]; Sumner et al.

(2007) [11] Annotation bottleneck Weak novelty and mechanism claims Dereplication; molecular networking; local libraries Wolfender et al. (2019)[16]; Qin et al. (2022) [9] Antioxidant-only evidence Overclaims; poor translation Mechanism-aligned assay panels; dose– response Prevention evidence logic QA/QC and contaminants Safety and credibility WHO-aligned QC; SOPs; stability testing WHO (2011); BPOM (2019) [2]

Table 3: Institutional roadmap metrics for Indonesian universities conducting prevention-oriented medicinal plant biochemistry research. Metric category Example indicator How to measure Benefit Governance readiness % projects with PIC/MAT + benefit-sharing plan annual compliance audit Legitimacy and durable partnerships Reproducibility % studies with vouchers + complete metadata + QC methods checklist Higher reliability and publishability Analytics capacity Shared LC–MS/NMR uptime and training core facility dashboard Faster dereplication and identification QA/QC Batch-to-batch marker variability ≤ threshold QC analytics report Standardization and safety support Translation # biomarker-based pilot studies with partners trial registry and reports Evidence ladder progression Sustainability % projects with cultivation/sourcing plan project governance review Reduced overharvesting risk

5. Conclusion

Medicinal plant biochemistry research can contribute to cancer prevention in Indonesia if it is designed around prevention-relevant biochemical targets, rigorous metabolite identification, and evidence ladders that include standardization, safety, and human biomarker studies. This synthesis provides a practical toolkit: a pathway map (Figure 1), an evidence‑to‑translation ladder (Figure 2), and tables summarizing targets, challenges, and institutional actions. The key recommendation is to treat governance readiness, taxonomy, metadata, QA/QC, and staged human evidence as core research outputs supported by shared analytics and partnerships. With these capabilities, Indonesian universities can produce credible, ethical, and scalable medicinal plant biochemistry programs that support prevention without overclaiming therapeutic effects.